MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC

Key Takeaways Merck's DOR/ISL matched Biktarvy in a phase III HIV study, meeting efficacy and safety goals.DOR/ISL's positive data support upcoming approval filings for treatment-naive HIV patients.The EU approved Keytruda SC, offering quicker dosing versus the IV version across all solid tumor uses.Merck (MRK) announced positive top-line results from a pivotal late-stage study evaluating its investigational, once-daily, oral, two-drug, single-tablet regimen of doravirine/islatravir [DOR/ISL (100 mg/0.25 mg ...